DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis

Information source: Mantecorp Industria Quimica e Farmaceutica Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis

Intervention: 0.5% prednisolone acetate cream (Drug); 0.1% betamethasone valerate cream (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: Mantecorp Industria Quimica e Farmaceutica Ltd.

Official(s) and/or principal investigator(s):
Mário C Pires, MD, Principal Investigator, Affiliation: Hospital Padre Bento de Guarulhos
Roberta F. J. Criado, MD, Principal Investigator, Affiliation: Faculdade d Medicina do ABC
Adilson Costa, MD, Principal Investigator, Affiliation: KOLderma

Overall contact:
Cláudia Domingues, Phone: 55115188.5237, Email: cdomingues@mantecorp.com


Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events. Conditions sensitive to corticosteroids require formulations with mild to moderate potency while high-potency corticosteroids era required in less responsive conditions. The aim of the present study is to compare the safety and efficacy of prednisolone acetate 0. 5% cream (mild-potency non-fluoridated corticosteroid) versus betamethasone valerate 0. 1% cream (high-potency fluoridated corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). The study hypothesis is that 0. 5% prednisolone cream will be as effective as 0. 1% betamethasone cream and will be an alternative option to treat corticosensitive dermatosis in body areas where the use of fluoridated corticosteroids is contraindicated, such as the face.

Clinical Details

Official title: Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Evaluate efficacy and safety of 0.5% prednisolone cream in comparison to 0.1% betamethasone cream in the treatment of corticosensitive dermatosis.

Secondary outcome: Evaluate physicians' and patients' perception of the efficacy and tolerability of treatment.


Minimum age: 12 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Subjects with corticosensitive dermatosis (atopic dermatitis, contact dermatitis,

seborrheic dermatitis, psoriasis) mild to moderate in intensity;

- Compliance of the subject to the treatment protocol;

- Agreement with the terms o the informed consent by the participants

- Subjects who did not use the following medicines before inclusion: topical

corticosteroids or other therapies to dermatitis (30 days); oral corticosteroids (180 days); parenteral corticosteroids (180 days); immunomodulators/immunosuppressor (30 days); any drug under investigation (1 year); any therapy for the studied clinical conditions (180 days); keratolytic agents (30 days); emollient agents (30 days); tazarotene (30 days); vitamin D (topical or oral, 30 days); methotrexate (30 days); acitretin (2 years); UV light (30 days); PUVA therapy (30 days). Exclusion criteria:

- Pregnancy or risk of pregnancy

- Lactation

- History of allergy of any component of the formulations

- Other conditions considered by the investigator as reasonable for non-eligibility

- HIV positivity

- Drug abuse

- Subjects without previous response to topical corticosteroids

- Subjects with intense sun exposure within 15 days of the screening

Locations and Contacts

Cláudia Domingues, Phone: 55115188.5237, Email: cdomingues@mantecorp.com

Additional Information

Starting date: February 2010
Last updated: November 10, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017